Introduction

Levels of chronic disease have increased over the past several decades; some have done so dramatically. Environmental pollutants, including herbicides and byproducts from industrial chemical processes, have been implicated as possibly being responsible for some portion of this increase. To provide a few examples: exposures to environmental pollutants have been linked to diabetes, cancer, and cardiovascular, neurodegenerative, respiratory, renal, autoimmune, and other diseases; polychlorinated biphenyls impact immune suppression, cardiovascular disease, liver disease, diabetes, and changes in thyroid and reproductive function; chlorophenols and related compounds, which include chlorophenoxy herbicides and dioxins, are associated with genotoxicity and carcinogenicity; and several ecologic studies show that chlorophenoxy herbicide use in Minnesota, Montana, North Dakota, and South Dakota influences human mortality rates due to cancer, acute myocardial infarction, diabetes, and renal disease, as well as rates of birth anomalies.\(^9\)

The large number of diverse diseases associated with exposure to environmental pollutants suggests perturbation of a basic biological pathway underlining the mechanism. However, current methodological approaches have not fully explored these associations for several reasons. Conducting research involving such environmental exposures is difficult because these exposures (1) are often ill defined, (2) occur at low doses, and (3) may involve multiple chemicals. Therefore, linking specific environmental exposures to effects by use of the traditional toxicological model, which is based on exposure to a single agent at different doses, is rather challenging. It has been suggested that a series of transdisciplinary, mutually complementary studies at different levels (ecosystem, population, individual, and molecular) can address these problems.\(^9\)

A single study based on one of these levels cannot fully define the exposure–effect link. In addition, simultaneous or multiple exposures over time may cause subjects to become increasingly susceptible. This acquired susceptibility due to cumulative exposures needs to be accounted for in studies attempting to link environmental exposures and effects.\(^10\) Results from a recent study on environmental perchlorate exposure identified a pattern of biomarker associations that linked perturbation of iron homeostasis with adverse biological activity.\(^11\) Additional investigation suggests that other environmental exposures have this same capability.\(^12\) In the current paper, we examine further evidence that perturbation of iron homeostasis may be a widespread mechanistic pathway for adverse biological effects following exposure to environmental pollutants (Fig. 1). We selected several environmental pollutants based on their human exposure levels, in order to examine if current knowledge justifies this concept.
Iron Homeostasis

Iron is an essential micronutrient required for virtually every aspect of normal cell function. The ability of this metal to interact with $O_2$, reflecting a favorable oxidation–reduction potential, and its abundance in nature have led to its evolutionary selection for a wide range of biological functions. However, these properties of iron which prove so useful for catalysis also make it a threat to life via generation of reactive oxygen species. While living systems must have iron to survive, iron-catalyzed generation of superoxide ($O_2^-$), hydrogen peroxide ($H_2O_2$), and hydroxyl radical (·OH) presents a potential for oxidative stress. Such reactivity mandates that iron acquisition and distribution be tightly regulated. Consequently, living systems have evolved strategies to regulate the procurement of adequate iron for cellular function and homeostasis without major damage to biological macromolecules.

Cellular iron homeostasis is maintained by a coordinated expression of proteins involved in the import, export, storage, and utilization of this metal. Posttranscriptional control mediated by iron-regulatory proteins (IRPs) is essential. The IRP binds to cis-acting mRNA motifs termed iron-responsive elements (IREs) to regulate the expression of proteins involved in iron homeostasis. This includes stabilizing the mRNA of the divalent metal transport 1 importer (DMT1) and transferrin receptor 1 (TfR1) to promote translation and increase their expression while suppressing the synthesis of the storage protein ferritin. IRP1, the cytosolic counterpart of mitochondrial aconitase, is a bifunctional protein that, through [4Fe-4S] cluster assembly/disassembly, shifts from the aconitase to the IRP1 form in response to the intracellular iron concentrations. Accordingly, iron levels regulate RNA-binding capacity of IRP.

**Figure 1.** Normally, a homeostasis of iron (designated by the small red dots) exists in a cell with the metal present at a concentration sufficient to meet structural and metabolic requirements; this includes the nucleus and mitochondria (designated by the blue circular and gray ovoid structures, respectively) (A). Introduction of an environmental chemical (designated by the yellow spherical structures) disrupts iron homeostasis as it, or a catabolic product, complexes the available iron, causing a functional deficiency of the metal in the cell (B). In response to a reduction in intracellular iron, the cell generates superoxide as a ferrireductant and upregulates importers (eg, DMT1) in an attempt to reacquire requisite metal (C). In addition, the complex of the environmental chemical with the iron may support electron transport, and oxidant generation may directly result from the reactions of this product with the available reductant and hydrogen peroxide (C). Oxidative stress activates cell signaling and transcription factors and will provoke a release of mediators initiating inflammation, fibrosis, and apoptosis (C). If the cell is effective in altering its iron homeostasis by increasing iron delivery, some portion of the metal will be stored in the protein ferritin (designated by the brown rectangular structures) (D). The result is an adequate level of metal available to the cell, including the environmental chemical, for continued survival and function.
Perturbation of Iron Homeostasis by Environmental Pollutants

Environmental pollutants demonstrate a capability to complex iron, especially if their chemical structure includes a double bond and/or electron-negative functional groups containing an oxygen, nitrogen, or sulfur atom, capable of sharing electrons. Complexes of iron sharing at least two binding sites with the ligand are termed chelates. The attribute of iron complexation by environmental pollutants may reflect their original purpose, such as disruption of normal iron homeostasis (eg, the effectiveness of a pesticide can be explained by its capability to complex iron and diminish its availability to pests). Complex formation results from a reaction between available cellular iron and either the chemical itself or a metabolic product.

Many of these compounds, employed in the environment to restrict the growth or presence of specific pests, are phenolic compounds, while others are metabolized to phenols via cytochrome P450 following ingestion and inhalation. Phenolic compounds demonstrate a significant capability for iron chelation. In mammals, for example, dioxins are metabolized by cytochrome P450 to hydroxyphenol, which will complex intracellular sources of iron. Accordingly, exposure to either the environmental pollutant or a catabolic product, followed by iron complexation, can cause an immediate loss of functional iron from normal intracellular sites. Iron is critical to the function of cells. This is especially true for mitochondria as this organelle is central to the metabolism of cellular iron. Exposure to the pollutant or its catabolite, followed by its appropriation of iron, will challenge mitochondrial function. The cell is compelled to acquire further metal critical to its survival. IRPs are activated and changes in iron import are the result (eg, altered expression of DMT1 and TfR1 follows exposure to these pollutants). Therefore, while the immediate outcome of the exposure to an environmental pollutant or a catabolic product is a cellular deficiency of functional iron, iron homeostasis will be altered in response, resulting in increased import and accumulation of iron. A new equilibrium will be established between the cell sites requiring iron (eg, mitochondria) and the inappropriate chelator (ie, the environmental pollutant or its catabolite) in order to allow for continued survival. At the level of the cell and the tissue, these changes in iron homeostasis can be supported by alternations in either RNA or protein activity of IRP, DMT1, ferritin, and transferrin receptor. In a human being, this new equilibrium can be reflected by elevated concentrations of ferritin and lower transferrin-bound iron levels in the blood.

The response of the cell to environmental chemicals with elevation in the expression of proteins involved in iron import, storage, and export does not appear to be consistent with the model of reciprocal effects mediated via the IRE. However, the response of normal cells, tissues, and living systems to either an absolute iron deficiency or a true overload is unlikely to be relevant in the response to an exposure to an inappropriate chelator such as an environmental chemical. When an inappropriate chelator in a cell complexes endogenous iron and initiates the loss of metal from the host, either the cells will increase iron import or apoptosis will occur. As total iron in the cells is increased due to import, and some form of intracellular equilibrium must be maintained, storage of iron in ferritin will also be elevated. This is not a static response but one which will continue for as long as the inappropriate chelator (ie, the environmental chemical) persists in the cell.

An example of these effects has been observed in association with exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD). As a result of the central role of IRPs in the control of iron metabolism, their modulation by 2,3,7,8-TCDD leads to changes in their expression profile such as alterations of cellular levels of transferrin receptor and ferritin. Elevations in intracellular iron following dioxin exposures can be observed in mammalian cells. Animals treated with a single dose of 2,3,7,8-TCDD showed an increase of 41%–67% in iron absorption, reflecting immediate alterations in the metabolism of this metal. The major effect of the dioxin was demonstrated to be on the transfer of iron from the mucosa into the bloodstream rather than on the uptake of iron from the gut lumen. Elevated liver iron content was shown in animals treated with 2,3,7,8-TCDD, which further supports the capability of this chemical to disrupt iron homeostasis and affect iron accumulation.

The catabolism of some herbicides to phenolic compounds is comparable with the catabolism of other aromatic hydrocarbons with regard to their capacity to complex iron, and accordingly disrupts iron homeostasis. Benzo[a]pyrene is metabolized by cytochrome P450 to catechol, hydroquinone, 1,2,4-benzenetriol, and p-benzoquinone. These compounds are recognized to have the capability to complex iron. Naphthoquinones are similarly metabolized by cytochrome P450 to phenolic compounds and demonstrate an iron-chelating ability. Finally, benzo(a)pyrene is hydroxylated to phenols, which are predicted to affect iron homeostasis.

A related aromatic compound (and a phenol as well) is doxorubicin, an antineoplastic medication (an anthracycline antitumor antibiotic). Exposure to doxorubicin disrupts iron homeostasis and increases heart iron concentrations. At the cellular level, exposure to this compound increases iron import by affecting the transferrin receptor and elevating ferritin levels, comparable with aromatic hydrocarbons used as herbicides. Effects of this anthracycline on cell iron homeostasis can be reversed through a provision of excess metal. Clofibrate (2-[4-chlorophenoxyl]-2-methylpropionic acid ethyl ester) is another related aromatic hydrocarbon that was previously employed as a lipid-lowering agent. Clofibrate is not a phenolic compound but does have an oxygen-containing functional group (phenoxy) with a capacity to interact with cytochrome P450 and to complex iron. Similar to environmental pollutants, clofibrate exposure alters iron homeostasis through a differential regulation of IRPs. Exposure to clofibrate reduces hepatic iron efflux, thereby increasing cell iron concentrations in the liver. A clinical trial initiated in the mid-1960s,
showed that subjects treated with clofibrate had a 25% reduction of nonfatal myocardial infarction. However, overall mortality was significantly increased based on diverse causes of death, which included cancer. The structure of clofibrate is related to that of the herbicides 2,4-dichlorophenoxyacetic acid (2,4-D) and 4-chloro-2-methylphenoxyacetic acid, which similarly have been associated with elevations in cancer incidence. Some environmental pollutants without either phenol groups or modification by cytochromes can form complexes with iron. The herbicide glyphosate (N-(phosphonomethyl) glycine) forms complexes with iron in the soil, resulting in decreased iron concentrations in leaves and seeds and inhibition of ferric reductase activity in the treated plant. It has been suggested that glyphosate-treated crops may have decreased nutritional levels. In human beings, glyphosate chelates iron and other metals and is thought to be associated with disease. The environmental pollutant perchlorate has been observed to be associated with reduced serum iron in human beings. Complexation of iron by perchlorate may be the likely mechanism.

Subjects are exposed to many environmental chemicals identified in blood and urine, which may have the capability to complex cellular iron. However, their strength to complex iron, which may be based on their chemical structure, is often unknown and will have to be determined by laboratory studies. Some chemicals may be strong iron chelators, eg, dioxin and perchlorate, while others may be weak chelators. However, they all may contribute to perturbation of iron homeostasis resulting in decreased serum iron levels. We propose that a subject’s serum iron level may be a representative biomarker for cumulative exposure to environmental iron-chelating chemicals.

Regarding the fate of the inappropriate iron chelates, further investigation is required. Complexation of the cell by the compound will alter its properties of solubility, thus making prediction of its export from the cell difficult. In addition, it is unclear that such complexation is permanent. A dynamic exchange of iron and other cations is anticipated between the chelator and host.

Oxidative Stress after Exposure to Environmental Pollutants

Pathophysiological effects, including inflammation, fibrosis, and cancer, following exposures to xenobiotic agents, have been associated with oxidative damage to macromolecules such as lipids, proteins, and DNA. Oxidative stress is a commonly described mechanistic feature of the toxicity of environmental pollutants. Exposure to 2,4-D initiates oxidative stress in rat erythrocytes. Similarly, proteins (eg, glutathione) and their enzyme activities (eg, glutathione reductase, and superoxide dismutase) involved in oxidant generation and antioxidant function in red blood cells can be impacted by exposures to 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) and its metabolite 2,4,5-trichlorophenol (2,4,5-TCP). In an animal model involving subacute exposure to 2,4-D, tissue malondialdehyde levels, antioxidant enzyme (ie, catalase and superoxide dismutase) activities, and serum uric acid concentrations all reflected increased oxidative stress. In another animal model, polychlorinated biphenyl exposure increased the levels of superoxide dismutase and heme oxygenase and concentrations of oxidatively modified lipids and proteins, reflecting an oxidative challenge and resulting in oxidant-mediated injury.

Oxidative stress is frequently associated with disruption of iron homeostasis. A relationship between oxidant generation and disruption of iron homeostasis following exposures to environmental pollutants can result through two potential pathways. First, the environmental pollutant or a catalytic product can be postulated to complex with iron and function as a Fenton’s reagent catalyzing electron exchange and oxidant production. Excess iron associated with the exposure is subsequently toxic because the complexed ferrous iron reacts with the available hydrogen peroxides and lipid peroxides to generate hydroxyl and lipid radicals, respectively. These radicals, in turn, damage membrane lipids, proteins, and nucleic acids. Second, in response to diminished levels of essential intracellular iron following complexation of the metal by environmental pollutants or a catalytic product, the cell can generate superoxide as a ferrireductant in an effort to reacquire the metal. Cellular oxidant generation, specifically superoxide, is known to follow exposure to iron deficiency. This production of oxygen-based radicals functions in the remedial response to iron loss following complexation of the metal. Superoxide, produced by the living system, tissue, cell, and organelle in response to iron deficit, assists in the import of this requisite metal by chemically reducing ferric iron to ferrous iron. This ferrireduction is an essential, and frequently limiting, reaction in such iron import and can be achieved in many cell types using superoxide.

Host Response to Disruption in Iron Homeostasis after Exposure to Environmental Pollutants

The response of a living system to complexation of iron by inappropriate chelators, such as that proposed for environmental pollutants, can include a systemic decrease in the available functional metal. Teleologically, microbial utilization of host iron was the challenge that probably accounts for the development of this response. The host reacts with an exploitation of its own metal by isolating the iron into the reticuloendothelial system, where it is considered less accessible to an inappropriate chelator, such as a microbe or a xenobiotic agent. This response is recognized as a component of the acute-phase reaction. If the exposure is prolonged, an anemia of chronic disease can result. Comparable to microbes and other xenobiotic agents, the complexation of host iron by environmental pollutants is proposed to initiate an attempt by the exposed individual to sequester its metal. The decreased iron level will reflect both the chelating capacity of the environmental chemical and the host’s acute-phase response to that
chemical. Accordingly, exposures to environmental pollutants impact indices of the acute-phase response, serum iron, and indices of red blood cell production. Such an acute-phase response has been documented following occupational exposure to environmental pollutants (i.e., dieldrin and pentachlorophenol). Similarly, the acute-phase reaction includes a loss of functional iron. With continued exposures, this can lead to anemia. Herbicide exposures have been associated with decrements in red blood cell counts, hemoglobin, and hematocrit values, which are predicted to result following significant and prolonged contact.

**Exposures to environmental pollutants and human health.** Exposures to environmental pollutants have been associated with diseases that are predicted to disclose a relationship with disrupted iron homeostasis. A few examples are briefly discussed here to support this viewpoint.

**Prenatal and neonatal effects.** Pregnancy is a state of high iron demand. However, it is estimated that only 20% of reproductive-aged women worldwide have an iron reserve that is optimal for the development of the fetus. Exposure of the mother to environmental pollutants that have the capability to perturb iron homeostasis and diminish available concentrations may adversely affect the development of the fetus. An example of such a pollutant is perchlorate. It was shown in a previous study that increasing urinary perchlorate concentrations were associated with decreasing serum iron concentrations among pregnant women. Decreased availability of iron resulting from a reaction of the environmental pollutant with maternal iron pools may preferentially influence the levels in the fetus as a result of its exceptional need and the delicate balance of the metal in the developing life. Iron is needed for cell growth and cell cycle progression. Low iron concentrations block cellular proliferation by impinging on pathways that control cell division. Iron chelation can arrest cell cycle progression in late G1, before the G1/S border. Accordingly, an increased incidence of birth defects can potentially be associated with exposures to environmental pollutants. It has been observed that children who were iron deficient at birth have lower cognitive skills.

**Endocrine disease.** Iron homeostasis influences endocrine function. For example, iron deficiency impairs thyroid hormone synthesis, possibly by reducing the activity of heme-dependent thyroid peroxidase, and is a common finding in patients with decreased thyroid activity. Iron treatment can provoke both an increase of T4 and a decline of TSH. Deficiency of the metal following exposures to environmental pollutants is predicted to influence thyroid function with hypothyroidism resulting. Such an impact has been described with decrements in indices of thyroid function following exposures to environmental pollutants, including perchlorate.

**Infections.** A connection exists between infection and disruption of iron homeostasis following exposures to different xenobiotic agents. The same relationship is proposed following exposures to environmental pollutants. The regulation of iron metabolism is affected by exposure to either the chemical or its metabolite, complexing the metal and thereby decreasing available functional iron concentrations. However, total iron concentrations increase with the exposed cells and tissues upregulating iron importers in order to compete for the metal and allow cell survival. The increased total iron in the exposed cells and tissues will be reflected by elevated ferritin levels in the host. There is an absolute dependency of all life on iron availability. With very few exceptions (e.g., lactobacilli which substitute manganese for iron), microbes require host iron in order to proliferate. The pathogen’s survival and virulence are directly related to its success in competing for the available iron in the host. Therefore, exposures to environmental pollutants will elevate the risk for infection by increasing total iron levels in cells, tissues, and living systems.

**Metabolic syndrome.** This group of characteristics includes obesity, insulin resistance, hyperglycemia, and dyslipidemia, which are risk factors for several diseases such as cardiovascular disease, diabetes type 2, immune disorders, and liver diseases. Exposures to multiple environmental chemicals are suspected to contribute to this disorder according to the Parma consensus statement. It is proposed that perturbation of iron homeostasis, as a result of exposure to environmental chemicals, contributes to this metabolic disruption. Supporting the concept is a seven-year follow-up study showing that markers of iron metabolism are associated with insulin resistance in adipose tissue, liver, and muscle, which may affect impaired glucose metabolism and type 2 diabetes. A rat study on chronic, low-dose exposure to the widely used herbicide atrazine (2-chloro-4-ethylamino-S-triazine) showed that this herbicide induced abdominal obesity and insulin resistance due to impaired mitochondrial function. This herbicide has several nitrogen atoms and double bonds in its chemical structure and, therefore, may have the capability to form iron complexes.

**Chronic diseases.** Associations between exposures to environmental pollutants and increased incidence of chronic disease have been suggested. A disruption of iron homeostasis is proposed to participate in the pathogenesis of numerous chronic diseases including diabetes, cancer, and cardiovascular, cerebrovascular, and neurodegenerative diseases. Diabetes and cardiovascular disease may have been preceded by the metabolic syndrome. Changes in the concentrations of functional iron are recognized as a determinant in the pathogenesis as they are related to both oxidative stress and injury. Therefore, it is feasible that increases in the incidence and prevalence of these chronic diseases following exposures to environmental pollutants are associated with altered iron availability. Some examples are discussed.

An association between a disruption in iron homeostasis and peripheral insulin resistance has been demonstrated...
in epidemiological investigations. Among middle-aged men, those with higher levels of serum ferritin had higher insulin and glucose levels. Serum ferritin concentrations were an independent predictor of increased serum insulin levels among adults. Women with impaired glucose tolerance or gestational diabetes had higher serum ferritin values relative to women with normal glucose tolerance. Diabetes has been shown to be associated with a disruption of normal iron metabolism. Individuals with type 2 diabetes had higher levels of serum ferritin and nontransferrin-bound iron relative to healthy controls. Men with high iron stores were 2.4 times more likely to develop type 2 diabetes compared with men with lower stores. A potential benefit of iron depletion on insulin sensitivity and/or type 2 diabetes has been demonstrated with frequent blood donors having better insulin sensitivity and lower ferritin levels compared with nondonors. An increased number of lifetime blood donations was associated with decreased prevalence of type 2 diabetes in men. Iron chelation therapy with intravenous deferoxamine significantly improved metabolic control with a reduction in blood glucose and glycosylated hemoglobin levels among type 2 diabetics. Accordingly, a disruption in iron homeostasis with an accumulation in total metal following exposure to an environmental pollutant can potentially impact both insulin resistance and diabetes.

A disruption in iron homeostasis can also participate in cardiovascular disease. In women, the risk of heart disease increases following either natural or surgical menopause, which is associated with elevations in serum ferritin concentrations. Among men, there is an increase in the risk of coronary heart disease with elevated iron stores. Men with high body iron stores had a two- to threefold increase in risk of myocardial infarction compared with men with low body iron stores. Among randomly selected men with no symptomatic coronary artery disease at entry, the adjusted risk of acute myocardial infarction with serum ferritin >200 ng/mL was 2.2-fold higher than in those with lower serum ferritin with the odds ratio increasing by 0.2 for each 100 ng/mL increase in serum ferritin. Mechanistically, evidence for a participation of iron in atherosclerosis was suggested by the ability of the metal to oxidize low-density lipoprotein (LDL) and damage endothelial cells, by the observation of ferritin induction with the progression of atherosclerotic lesions, by the inhibition of endothelial cell damage and oxidation of LDL by chelators, and by the prevention of endothelial cell dysfunction and vascular smooth muscle proliferation by chelators. Altering iron metabolism with phlebotomy, systemic iron chelation treatment, or dietary iron restriction reduces atherosclerotic lesion size and/or increases plaque stability. Changes in iron stores during a five-year follow-up period modified the risk of atherosclerosis with the lowering of iron stores being beneficial and the further accumulation of iron increasing cardiovascular risk. Furthermore, studies on the effect of blood donation on the reduction of cardiovascular events support the postulate that iron stores can be associated with coronary artery disease. Therefore, increases in heart disease following exposure to environmental pollutants could result from host iron complexation and impact of total available metal.

Evidence also supports the participation of iron in cerebrovascular disease. Experimental iron overload induced by using an iron-rich diet causes larger infarct volumes after permanent middle cerebral arterial occlusion in rats. These results indicate that the severity of tissue injury with cerebrovascular occlusion can be proportional to total iron. Asymptomatic carotid atherosclerosis, assessed by duplex sonography, shows a strong correlation with iron stores in men and women. Higher serum ferritin concentrations can be associated with an increased risk of ischemic stroke. Increased ferritin concentrations, in both blood and cerebrospinal fluid, have been related to poor outcome in stroke patients. Increased serum ferritin concentrations before treatment also predict prognosis in patients with a higher risk of hemorrhagic transformation and brain edema. Treatment with an iron-deficient diet reduces neuronal necrosis and improves neurological status in animal models of global and focal cerebral ischemia. Following exposure to environmental pollutants, an accumulation in total iron concentration combined with a decrease of functional iron could account for the observed changes in cerebrovascular disease.

Perturbed iron homeostasis has been observed in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). In Alzheimer’s disease, increased levels of iron and ferritin have been noted pathologically in the cerebral cortex. Among those individuals suffering from Parkinson’s disease, iron accumulates at the sites of neuronal death. Among ALS patients, elevations in serum ferritin and transferrin saturation levels have been shown. It is feasible that altered iron homeostasis following exposure to environmental pollutants could contribute to the observed accumulations of this metal in neurodegenerative disease.

Regarding cancer, cohort studies have found that indices of iron metabolism are associated with an increased risk of cancer incidence and cancer mortality. Among persons with increased transferrin saturation, a daily intake of dietary iron of >18 mg is associated with an increased risk of cancer. A causal relationship is suggested by studies showing that blood donation (to reduce total body iron stores) is associated with lower cancer risk and that blood transfusion adversely affects cancer outcome. A randomized trial of subjects undergoing phlebotomy showed a significant reduction in overall cancer incidence with iron reduction. An association of iron intake with colorectal cancer risk has been observed among a cohort of the National Health and Nutrition Examination Survey I. The association between
elevations in biologically available iron and increased cancer may result from the antiapoptotic effect of the metal.131 Experimental study findings support a role of iron in chemically induced carcinogenesis and demonstrate that iron may initiate and promote carcinogenesis through the production of oxidative stress, facilitation of tumor cell growth, and modification of the immune system. Excessive accumulation of iron in hepatocytes causes hepatocellular injury, which leads to the development of hepatoma.135 A low iron diet resulted in a decrease in skin tumor incidence (both papillomas and carcinomas) and the number of tumors per mouse, as well as the conversion of papillomas to carcinomas.136 Comparable to diabetes, coronary artery disease, cerebrovascular disease, neurodegenerative disease, and cancer may be associated with a disruption in iron homeostasis initiated by the exposure to an environmental pollutant.

Conclusion
Based on previous investigations, various diseases have been shown to be associated with exposure to environmental pollutants. Multiple exposures over time may have cumulative effects and lead to increased susceptibility to disease. Mechanistically, we propose that this occurs through an impact of such pollutants on iron homeostasis. The disruption of iron homeostasis results from the initial interaction with environmental pollutants, ie, complexation of the metal by the chemical or its metabolic products with subsequent reductions in host cell and tissue levels of functional iron, and likely represents the most basic mechanism underlying the biological effects following such exposure. If the concept described in this investigation is confirmed, iron chelation may be the molecular-initiating event of the adverse outcome pathway of many environmental chemicals. Determination of their chelating capability will be of interest with regard to their association with adverse health effects.

Acknowledgments
The authors acknowledge the valuable comments by Michael Madden, Joachim Pleil, and the reviewers for Environmental Health Insights.

Disclaimer
The research described in this article has been reviewed in accordance with the U.S. Environmental Protection Agency policy and approved for publication. Approval does not signify that the contents necessarily reflect the views and policies of the agency.

Author Contributions
Conceived the concepts: DMS, AJG. Analyzed the data: DMS, AJG. Wrote the first draft of the manuscript: DMS, AJG. Contributed to the writing of the manuscript: DMS, AJG. Agree with manuscript results and conclusions: DMS, AJG. Jointly developed the structure and arguments for the paper: DMS, AJG. Made critical revisions and approved final version: DMS, AJG. Both authors reviewed and approved of the final manuscript.

REFERENCES
1. Mostafalou S, Abdollahi M. Pesticides and human chronic diseases: evidences, mechanisms, and perspectives. Toxicol Appl Pharmacol. 2013;268:157–77.
2. Carpenter DO. Polychlorinated biphenyls (PCBs): routes of exposure and effects on human health. Rev Environ Health. 2007;22:11–23.
3. Ibigioba EO, Odajdare EE, Chigor VN, et al. Toxicological profile of chlorophenols and their derivatives in the environment: the public health perspective. Scientific World Journal. 2013;2013:460215.
4. Garry VF, Kelly JT, Spazak JM, Edwards S, Griffith J. Survey of health and use characterization of pesticide applicators in Minnesota. Arch Environ Health. 1994;49:337–43.
5. Schreinemachers DM, Creason JP, Garry VF. Cancer mortality in agricultural regions of Minnesota. Environ Health Perspect. 1999;107:205–11.
6. Schreinemachers DM. Cancer mortality in four northern wheat-producing states. Environ Health Perspect. 2000;108:873–81.
7. Schreinemachers DM. Birth malformations and other adverse perinatal outcomes in four U.S. Wheat-producing states. Environ Health Perspect. 2003;111:1259–64.
8. Schreinemachers DM. Mortality from ischemic heart disease and diabetes melitus (type 2) in four U.S. wheat-producing states: a hypothesis-generating study. Environ Health Perspect. 2006;114:186–93.
9. Pekkanen J, Pearce N. Environmental epidemiology: challenges and opportunities. Environ Health Perspect. 2001;109:1–5.
10.动静 P, Khan AE, Vlaanderen J, Vermeulen R. The impact of new research technologies on our understanding of environmental causes of disease: the concept of clinical vulnerability. Environ Health. 2009;8:54.
11. Schreinemachers DM, Ghio AJ, Sobus JR, Williams MA. Perchlorate exposure is associated with oxidative stress and indicators of serum iron homeostasis among NAHES 2005–2008 subjects. Biomark Insights. 2015;10:9–19.
12. Guo W, Zhang J, Li W, Xu M, Liu S. Disruption of iron homeostasis and resultant health effects upon exposure to various environmental pollutants: a critical review. J Environ Sci. 2015;34:155–64.
13. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004;117:285–97.
14. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Annu N Y Acad Sci. 2004;1012:1–13.
15. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol. 2006;2:406–14.
16. Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr. 2008;28:197–213.
17. Wallander ML, Leibold EA, Eisenstein RS. Molecular control of vertebrate iron homeostasis by iron regulatory proteins. Bioclin Biochem Acta. 2006;176:688–89.
18. Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE. Receptor mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res. 1987;18:299–304.
19. Mims MP, Pchal JT. Divalent metal transporter 1. Hematology. 2005;10:339–45.
20. Aziz N, Munro HN. Iron regulates ferritin mRNA translation through a segment of its 5′ untranslated region. Proc Natl Acad Sci U S A. 1992;89:11730–4.
21. Perron NR, Brumaghim JL. Purification and characterization of cytosolic aconitase from beef liver and its relationship to the iron-responsive element binding protein. Proc Natl Acad Sci U S A. 1992;89:11730–4.
22. Kennedy MC, Mende-Mueller L, Blondin GA, Beinert H. Characterization of cytosolic aconitase from beef liver and its relationship to the iron-responsive element binding protein. Proc Natl Acad Sci U S A. 1992;89:11730–4.
23. Chobot V, Hadacek F. Iron and its complexation by phenolic cellular metabolites. Biotechnol Appl Biochem. 2010;56:1–14.
24. Sakaki T, Yamamoto K, Ikushiro S. Possibility of application of cytochrome c551 as an iron-sensor in molecular electronics. Biotechnol Appl Biochem. 2009;53:12;77–80.
25. Braissant C, Djidjou-Demasse C, Chen YL, et al. From oxidative stress to chemical weapons. Plant Signal Behav. 2010;5:4–8.
26. Cairo G, Recalcati S, Pietrangelo A, Minotti G. The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med. 2002;32:1237–43.
27. Basaraba RJ, Bielefeldt-Ohmann H, Eschelbach EK, et al. Increased expression of host iron-binding proteins precedes iron accumulation and calcification of primary lung lesions in experimental tuberculosis in the guinea pig. Tuberculosis (Edinb). 2008;88:69–79.

ENVIRONMENTAL HEALTH INSIGHTS 2016:10 | 41
58. Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cell-
lular differentiation and synergizes with differentiating agents in acute myeloid
leukemia. J Exp Med. 2010;207:71–50.
59. Chastoun TB, Watts RN, Yuan J, Richardson DR. Potent antitumor activity
of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydra-
zone involves fentont-derived free radical generation. Clin Cancer Res. 2004;10:
7365–74.
60. Dendoerfer A, Heiblender M, Hellwig-Burgh T, Johren O, Qdri F, Dominick P.
Deferoxamine induces prolonged cardiac preconditioning via accumulation of
oxygen radicals. Free Rad Biol Med. 2005;38:117–24.
61. Cakmak I, van de Wetering DA, Marschner H, Bienfait HF. Involvement of
superoxide radical in extracellular ferric reduction by iron-deficient bean roots.
Plant Physiol. 1987;85:310.
62. Rose AL, Saloom TT, Liu N, Nielan BA, Waite TD. Use of superoxide as an
electron shuttle for iron acquisition by the marine cyanobacterium Lyngbya
majacca. Environ Sci Technol. 2005;39:7078–15.
63. Srinivasan C, Liba A, Inlay JA, Valentine JS, Gralla YB. Yeast lacking super-
oxide dismutase(s) show elevated levels of free iron as measured by whole cell
electron paramagnetic resonance. J Biol Chem. 2000;275:29187–92.
64. Ghio AJ, Nozik-Grayck E, Turi J, et al. Superoxide-dependent iron uptake:
a new role for anion pesticide exposure. J Biol Chem. 1976;19:1645–51.
65. Takahashi W, Reichert ER, Gung GC, Hokama Y. Acute phase proteins and
peptide exposure. Life Sci. 1976;19:1645–51.
66. Patel JP, Patil AJ, Sontake AV, Govindwar SP. Occupational pesticides expo-
sure of sprayers of grape gardens in western Maharashtra (India): effects on
liver and kidney function. J Basic Clin Physiol Pharmacol. 2013;24:345–56.
67. Hussain R, Mahmood F, Khan MZ, Muhammad F. Pathogenic and geno-
tonic effects of atrazine in male Japanese quail (Coturnix japonica). Environ
Toxicol. 2013;36:1–8.
68. Cao C, O’Brien KO. Pregnancy and iron homeostasis: an update. Nutr Rev.
2013;71:35–51.
69. Ledermann HM, Cohen A, Lee JW, Freedman MH, Gelfand EW. Deferoxamine:
a reversible S-phase inhibitor of human lymphocyte proliferation. Blood. 1984;
64:664–72.
70. Hilti D, Panayiotidis P, Hoffbrand AV. Iron chelators induce apoptosis in pro-
iferating cells. Br J Haematol. 1995;98:181–7.
71. McArdele HJ, Gambling L, Kennedy C. Iron deficiency during pregnancy:
the consequences for placental function and fetal outcome. Proc Nutr Soc.
2006;65:236–43.
72. Collard KJ. Iron homeostasis in the neonate. Pediatr. 2009;123:1208–16.
73. Radawski FC, Johnson RW. Perinatal iron deficiency and neurocognitive
development. Front Hum Neurosci. 2014;4(article 585):1–11.
74. Duntas LH, Papanastrous L, Mantzou E, Koutras DA. Incidence of sidero-
penia and effects of iron repletion treatment in women with subclinical hypothy-
roidism. Exp Clin Endocrinol Diabetes. 1999;107(6):356–60.
75. Zimmermann MB, Körhle J. The impact of iron and selenium deficiencies on
iodine and thyroid metabolism: biochemistry and relevance to public health.
Thyroid. 2002;12:867–78.
76. Steinman M, Miller MD, Smith AH. Perchlorate in drinking water during
pregnancy and neonatal thyroid hormone levels in California. J Occup Environ
Health. 2010;25(4):217–24.
77. Baccarelli A, Giaconini SM, Corbetta C, et al. Neonatal thyroid function in
Serero 25 years after maternal exposure to dioxin. PLoS Med. 2006;3:e61.
78. Ghio AJ. Particle exposures and infections. Inhalation. 2014;42:459–67.
79. Weinberg ED. Iron availability and infection. Biochem Biophys Acta. 2009;
1790:600–5.
80. Repetto R, Baliga SS. Pesticides and immunosuppression: the risks to public
health. Health Policy Plan. 1997;12:97–106.
81. Dallaire F, Dewailly E, Muckle G, et al. Acute infections and environmental
exposure to organochlorines in Inuit infants from Nunavik. Environ Health
Perspect. 2004;112:1359–65.
82. Heindel JJ, vom Saal FS, Blumberg B, et al. Parabens consensus statement on
metabolic disruptors. Environ Health. 2015;14:54.
High stored iron levels are associated with excess risk of myocardial infarction in men and women over 3 years: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. *Diabetes Care* 2009;32:230–5.

Lao TT, Tam KB, Maternal serum ferritin and gestational impaired glucose tolerance. *Diabetes Care* 2009;32:113–29.

Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes in humans. *Biochim Biophys Acta*. 2009;1790:671–81.

Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT. Association between iron stores and non-insulin dependent diabetes in men: a mechanistic approach. *Toxicol Lett*. 2014;230:85–103.

Schimas I, Leon ME. Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. *Int J Environ Res Public Health*. 2014;11:4449–527.

Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. *Diabetes Care* 1998;21:62–8.

Pomeran P, Pean F, Driis F, et al. Insulin Resistance Syndrome (DESIR) Study Group. Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3 years: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. *Diabetes Care*. 2006;29:2090–4.

Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB. The role of iron in type 2 diabetes in humans. *Biochim Biophys Acta*. 2009;1790:1–14.

Lao TT, Chan PL, Tam KG. Gestational diabetes mellitus in the last trimester—a feature of maternal iron excess? *Diabet Med*. 2001;18:218–23.

Lao TT, Tam KG. Maternal serum ferritin and gestational impaired glucose tolerance. *Diabetes Care* 1997;20:1368–9.

Chen X, Scholl TO, Stein TP. Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women: The Camden study. *Diabetes Care*. 2006;29:1077–82.

Tzortzis E, Kishnani S, T. Eggen T. High maternal hemoglobin and ferritin values act as risk factors for gestational diabetes. *Int J Gynecol Obstet*. 2004;84:259–61.

Lee DH, Liu DY, Jacobs DR Jr, et al. Common presence of non-transferrin-bound iron among patients with type 2 diabetes. *Diabetes Care*. 2006;29:1090–5.

Salonen JT, Tuomilehto J, Nyyssonen K, Laakka HM, Punnunen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. *BMJ*. 1998;317:827.

Liu Q, Sun L, Tan Y, Wang G, Lin X, Cai L. Role of iron deficiency and over-load in the pathogenesis of diabetes and diabetic complications. *Carn Med*. 2009;13:111–15.

Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. *Diabetes Care*. 2007;30:1926–33.

Ascherio A, Rinne EB, Giorgannaci E, Willett WC, Stampfer MJ. Blood donations and risk of coronary heart disease in men. *Circulation*. 2001;103:52–7.

Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion. *Clin Chem*. 2005;51:1201–5.

Cutler P. Deferoxamine therapy in high-ferritin diabetes. *Diabetes*. 1989;38:1207–10.

Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. *Ann Med*. 1976;8:447–52.

Tuomilehto J, Nyyssonen K, Laakka HM, Punnunen K. Relation between iron stores and the risk of acute myocardial infarction in men. *Circulation*. 1998;97:1461–6.

Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppainen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. *Circulation*. 1992;86:803–11.

Van Lenten BJ, Priewe J, Navah M, Hama S, Louis AJ, Fogelman AM. Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. *J Clin Invest*. 1995;95:2104–10.

Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. *Atherosclerosis Thromb Vasc Biol*. 2004;24:949–54.

de Valk B, Mars JI. Iron, atherosclerosis, and ischemic heart disease. *Arq Intern Med*. 1993;159:1542–8.

Asmis R, Begley JG. Oxidized LDL promotes peroxide-mediated mitochondrial dysfunction and cell death in human macrophages: a caspase-3-independent pathway. *Circ Res*. 2003;92:260–9.

Matthews AJ, Vercellone GM, Menchaca HJ, et al. Iron and atherosclerosis: inhibition by the iron chelator deferriprone (L3). *J Surg Res*. 1997;73:35–40.

Meyers DG. The iron hypothesis—does iron cause atherosclerosis? *Clin Cardiol*. 1996;19:925–9.

Sullivan JL. Iron in arterial plaque: modifiable risk factor for atherosclerosis. *Eur J Pharmacol*. 2009;570:218–23.

Kiechl S, Willeit J, Egger G, Poebe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. *Circulation*. 1997;96:3300–7.

Meyers DG, Strickland D, Malooy PA, Seburg JK, Wilson JE, McMansu BF. Possible association of a reduction in cardiovascular events with blood donation. *Heart*. 1997;78:188–93.

Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. *BMJ*. 1997;314:793–4.

Castellanos M, Puig N, Carbolln T, et al. Iron intake increases infarct volume after permanent middle cerebral artery occlusion in rats. *Brain Res*. 2002;952:1–6.

Kiechl S, Aichner F, Gerstenbrand F, et al. Body iron stores and presence of carotid atherosclerosis. Results from the Bruneck Study. *Atherosclerosis*. 1995;114:25–30.

Davalos A, Fernandez-Real JM, Ricart W, et al. Iron-related damage in acute ischemic stroke. *Stroke*. 1994;25:1543–6.

van der ADL, Grobbbee DE, Roest M, Mars JJ, Voorhij HA, van der Schouw YT. Serum ferritin is a risk factor for stroke in postmenopausal women. *Stroke*. 2005;36:1637–41.

Millan M, Sobrino T, Castellanos M, et al. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. *Stroke*. 2007;38:90–5.

Carbonell T, Rama R. Iron, oxidative stress and early neurological deterioration in ischemic stroke. *Carn Med*. 2007;14:857–74.

Hadhizhiva M, Kirches E, Mawrin C. Review: iron metabolism and the role of iron in neurodegenerative disorders. *Neuropsychol Appl Neurobiol*. 2014;40:240–57.

van Duijn S, Nabuurs RJ, Van Duinen SG, Natté R. Comparison of histological techniques to visualize iron in paraffin-embedded brain tissue of patients with Alzheimer’s disease. *J Histchem Cytochem*. 2013;61:785–92.

Mochizuki H, Yasuda T. Iron accumulation in Parkinson’s disease. *J Neural Transm*. 2012;119:1511–4.

Veyrat-Durebex C, Corcia P, Mucha A, et al. Iron metabolism disturbance in a French cohort of ALS patients. *Riass Med Res*. 2014;48:2572.

Mainous AG III, Gill JM, Everett CJ. Transferrin saturation, dietary iron intake, and death from colorectal cancer in the NHANES III cohort. *J Am Coll Nutr*. 2004;23(5):459–65.

Wurzelman JI, Silver A, Schreinemachers DM, Sandler RS, Everson RB. Iron intake and the risk of colorectal cancer. *Ann Fam Med*. 2005;3:131–7.

Edgern G, Reilley M, Hajgirn H, et al. Donation frequency, iron intake, and risk of cancer among blood donors. *J Natl Cancer Inst*. 2008;100:572–9.

Merk K, Mattsson B, Mattsson A, Holm G, Goldbring B, Bjoekholm M. The incidence of cancer among blood donors. *Int J Epidemiol*. 1990;19:505–9.

Swede H, Hajduk AM, Sharma J, et al. Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort. *Int J Cancer*. 2014;134:1662–70.

Deugnier Y. Iron and liver cancer. *Alcohol*. 2003;30:145–50.

Wurzelman JI, Silver A, Schreinemachers DM, Sandler RS, Everson RB. Iron intake and the risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev*. 1996;5:503–7.

Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. *Sci Cancer*. 2009;2009:9–16.

Bhasin G, Kauser H, Abar B. Low iron state is associated with reduced tumor promotion in a two-stage mouse skin carcinogenesis model. *Food Chem Toxicol*. 2002;40:1105–11.